Covid Vaccine Efficacy
- All
- News
- Videos
-
Pfizer Chief Ignores Questions About Covid Vaccine's Efficacy In Davos: Report
Albert Bourla, Chief Executive Officer of US-based pharmaceutical giant Pfizer, encountered a series of tough questions about the efficacy of its Covid vaccine on the sidelines of the ongoing World Economic Forum, but he repeatedly ignored them.
-
Sudden Covid Outbreaks Show "Lack Of Efficacy" Of Chinese Vaccines: Report
China's sudden COVID-19 outbreaks "demonstrate a lack of effectiveness of its vaccines", prompting global concerns, particularly in nations where Beijing's vaccines have been accepted, Tibet Press reported.
-
Bharat Biotech To Launch 1st Nasal Covid Vaccine, No Efficacy Data Released
Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergency situations for those above the age of 18 years. iNCOVACC will become the first intranasal vaccine in the world.
-
Covid Vaccination Improves Efficacy Of Cancer Treatment, Says Study
Researchers were concerned that Covid vaccine would reduce the effectiveness of drugs used to treat nasopharyngeal cancer, a type of throat cancer, but a new study shows the opposite.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
US Health Authority Says Moderna Covid Vaccine Effective In Under-Fives
US health authorities confirmed on Friday that data provided by drug-maker Moderna on the efficacy of its Covid-19 vaccine among very young children were accurate.
-
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy, Says Bharat Biotech
The World Health Organisation said on Saturday it has suspended supply through United Nations agencies of COVID-19 vaccine Covaxin, produced by India's Bharat Biotech, to allow the manufacturer to upgrade facilities.
-
Covishield Dose Gap Reduced To 8-16 Weeks From 12-16
India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.
-
Covid Booster Efficacy Reduces Significantly By 4th Month: US Study
The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC) said Friday.
-
How Long Does A Covid Booster Shot Offer Protection? US Study Answers
The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC) said Friday.
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
Covid Vaccines Show High Efficacy Against Severe Omicron: US Data
Covid-19 vaccines and boosters continued to have very high efficacy against severe outcomes during the Omicron wave of the virus, a large real-world study from the US Centers for Disease Control and Prevention (CDC) showed Friday.
-
Centre Fact Checks Video Questioning Vaccine Efficacy In Children
The Central government busted the claims made in a video on the social media platforms raising questions over the efficacy of COVID-19 vaccine being administered in 15-18 years age group
-
Amid Omicron Fears, Government To Study Benefit Of Booster Dose: Sources
The government will conduct a medical study - on 3,000 fully vaccinated individuals - to assess the efficacy of a Covid vaccine booster against the Omicron variant, Health Ministry sources said Friday.
-
Case Data From UK, Vaccine Efficacy Mark Small Victories In Omicron Battle
Two vaccine manufacturers said their shots offered protection against Omicron, as UK data suggested it may cause proportionally fewer hospitalisations than the Delta coronavirus variant, supporting conclusions reached in South Africa.
-
Pfizer Chief Ignores Questions About Covid Vaccine's Efficacy In Davos: Report
Albert Bourla, Chief Executive Officer of US-based pharmaceutical giant Pfizer, encountered a series of tough questions about the efficacy of its Covid vaccine on the sidelines of the ongoing World Economic Forum, but he repeatedly ignored them.
-
Sudden Covid Outbreaks Show "Lack Of Efficacy" Of Chinese Vaccines: Report
China's sudden COVID-19 outbreaks "demonstrate a lack of effectiveness of its vaccines", prompting global concerns, particularly in nations where Beijing's vaccines have been accepted, Tibet Press reported.
-
Bharat Biotech To Launch 1st Nasal Covid Vaccine, No Efficacy Data Released
Bharat Biotech's needle-free intranasal Covid vaccine has been cleared for restricted use in emergency situations for those above the age of 18 years. iNCOVACC will become the first intranasal vaccine in the world.
-
Covid Vaccination Improves Efficacy Of Cancer Treatment, Says Study
Researchers were concerned that Covid vaccine would reduce the effectiveness of drugs used to treat nasopharyngeal cancer, a type of throat cancer, but a new study shows the opposite.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
US Health Authority Says Moderna Covid Vaccine Effective In Under-Fives
US health authorities confirmed on Friday that data provided by drug-maker Moderna on the efficacy of its Covid-19 vaccine among very young children were accurate.
-
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy, Says Bharat Biotech
The World Health Organisation said on Saturday it has suspended supply through United Nations agencies of COVID-19 vaccine Covaxin, produced by India's Bharat Biotech, to allow the manufacturer to upgrade facilities.
-
Covishield Dose Gap Reduced To 8-16 Weeks From 12-16
India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.
-
Covid Booster Efficacy Reduces Significantly By 4th Month: US Study
The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC) said Friday.
-
How Long Does A Covid Booster Shot Offer Protection? US Study Answers
The efficacy of third doses of the Pfizer and Moderna mRNA vaccines wanes substantially by the fourth month after administration, a new study by the US Centers of Disease Control and Prevention (CDC) said Friday.
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
Covid Vaccines Show High Efficacy Against Severe Omicron: US Data
Covid-19 vaccines and boosters continued to have very high efficacy against severe outcomes during the Omicron wave of the virus, a large real-world study from the US Centers for Disease Control and Prevention (CDC) showed Friday.
-
Centre Fact Checks Video Questioning Vaccine Efficacy In Children
The Central government busted the claims made in a video on the social media platforms raising questions over the efficacy of COVID-19 vaccine being administered in 15-18 years age group
-
Amid Omicron Fears, Government To Study Benefit Of Booster Dose: Sources
The government will conduct a medical study - on 3,000 fully vaccinated individuals - to assess the efficacy of a Covid vaccine booster against the Omicron variant, Health Ministry sources said Friday.
-
Case Data From UK, Vaccine Efficacy Mark Small Victories In Omicron Battle
Two vaccine manufacturers said their shots offered protection against Omicron, as UK data suggested it may cause proportionally fewer hospitalisations than the Delta coronavirus variant, supporting conclusions reached in South Africa.
